Skip to main content
SpringerLink
Log in

Cytoprotective Effect of Valeriana officinalis Extract on an In Vitro Experimental Model of Parkinson Disease

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Parkinson′s disease (PD) is one of the most important neurodegenerative worldwide disorders. The potential cytoprotective effects of aqueous extract of Valeriana officinalis on rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells were demonstrated. The cytotoxicity, cell viability and analysis of cellular morphology were performed by MTT-tetrazole (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and phase contrast microscopy, respectively. Significant changes in the cellular morphology, and condensation of the cell body could be observed when cells were treated with 300 nM rotenone for 48 h. Three different concentrations of Valeriana officinalis extract were used (0.049, 0.098 and 0.195 mg/mL). These extracts brought about an increase of 7.0 ± 1.3%, 14.5 ± 1.3% and 14.5 ± 3.2% in cell viability. Our results indicated that neuroprotector action of the Valeriana officinalis extract provides support for later studies as they help understanding this drug for the development of cytoprotective various therapies in PD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302(5646):819–822

    Article  PubMed  CAS  Google Scholar 

  2. Spillantini MG, Schmidt ML, Lee VM et al (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839–840

    Article  PubMed  CAS  Google Scholar 

  3. Greenamyre JT, Hastings TG (2004) Biomedicine: Parkinson’s-divergent causes, convergent mechanisms. Science 304:1120–1122

    Article  PubMed  CAS  Google Scholar 

  4. Cowan WM, Kandel ER (2001) Prospects for neurology and psychiatry. J Am Med Assoc 285:594–600

    Article  CAS  Google Scholar 

  5. Eberhardt O, Schulz JB (2003) Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson’s disease. Toxicol Lett 4:135–151

    Article  CAS  Google Scholar 

  6. Gorell JM, Peterson EL, Rybicki BA et al (2004) Multiple risk factors for Parkinson’s disease. J Neurol Sci 217:169–174

    Article  PubMed  Google Scholar 

  7. Sulzer D (2007) Multiple hit hypotheses for dopamine neuron loss in Parkinson’s disease. Trends Neurosci 30(5):244–250

    Article  PubMed  CAS  Google Scholar 

  8. Gorell JM, Johnson CC, Rybicki BA et al (1998) The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 50:1346–1350

    PubMed  CAS  Google Scholar 

  9. Davies KJ (1995) Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 61:1–31

    PubMed  CAS  Google Scholar 

  10. Greenamyre JT, Sherer TB, Betarbet R et al (2001) Complex I and Parkinson’s disease. IUBMB Life 52:135–141

    Article  PubMed  CAS  Google Scholar 

  11. Li N, Ragheb K, Lawler G et al (2002) Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278:8516–8525

    Article  PubMed  CAS  Google Scholar 

  12. Sipos I, Tretter L, Adam-Vizi V (2003) Quantitative relationship between inhibition of respiratory complexes and formation of reactive oxygen species in isolated nerve terminals. J Neurochem 84:112–118

    Article  PubMed  CAS  Google Scholar 

  13. Seaton TA, Cooper JM, Schapira AH (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 777:110–118

    Article  PubMed  CAS  Google Scholar 

  14. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson’s disease. Bioessays 24:308–318

    Article  PubMed  CAS  Google Scholar 

  15. Houghton PJ (1999) The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51:505–512

    Article  PubMed  CAS  Google Scholar 

  16. Piccinelli AL, Arana S, Caceres A et al (2004) New lignans from the roots of Valeriana prionophylla with antioxidative and vasorelaxant activities. J Nat Prod 67:1135–1140

    Article  PubMed  CAS  Google Scholar 

  17. Carlini EA (2003) Plants and the central nervous system. Pharmacol Biochem Behav 75:501–512

    Article  PubMed  CAS  Google Scholar 

  18. Hobbs C (1989) Valerian. Herbal Gram 21:19–34

    Google Scholar 

  19. Hori H, Ohmori O, Shinkai T et al (2000) Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 23:170–177

    Article  PubMed  CAS  Google Scholar 

  20. Molina-Jimenez MF, Sanchez-Reus MI, Benedi J (2003) Effect of fraxetin and myricetin on rotenone-induced cytotoxicity in SH-SY5Y cells: comparison with N-acetylcysteine. Eur J Pharmacol 472:81–87

    Article  PubMed  CAS  Google Scholar 

  21. Cumming JL, Zhong K (2006) Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies. Nat Rev Drug Discov 5:64–74

    Article  Google Scholar 

  22. Carol AN, Linda AA (1996) Herbal medicines—a guide for health-careprofessionals. The Pharmaceutical Press, London

    Google Scholar 

  23. Marder M, Viola H, Wasowskia C et al (2003) 6-Methylapigenin and hesperidin: new Valeriana flavonoids with activity on the CNS. Pharmacology. Biochem Behav 75:537–545

    Article  CAS  Google Scholar 

  24. Malva JO, Santos S, Macedo T (2004) Neuroprotective properties of Valeriana officinalis extracts. Neurotox Res 6:131–140

    PubMed  Google Scholar 

  25. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 12:203–210

    Article  Google Scholar 

  26. Tan S, Sagara Y, Liu Y et al (1998) The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141:1423–1432

    Article  PubMed  CAS  Google Scholar 

  27. Sherer TB, Betarbet R, Greenamyre JT (2002) Environment, mitochondria, and Parkinson’s disease. Neuroscientist 8:192–197

    PubMed  CAS  Google Scholar 

  28. Mattson MP (2007) Mitochondrial regulation of neuronal plasticity. Neurochem Res 32:707–715

    Article  PubMed  CAS  Google Scholar 

  29. Valverde G De Andrade D, Madureira de Oliveria D, Barreto G, Bertolino LA, Saraceno E, Capani F, Giraldez LD (2008) Effects of the extract of Anemopaegma mirandum (Catuaba) on Rotenone-induced apoptosis in human neuroblastomas SH-SY5Y cells. Brain Res 1198:188–196

    Article  PubMed  CAS  Google Scholar 

  30. Chung WG, Miranda CL, Maier CS (2007) Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells. Brain Res 1176:133–142

    Article  PubMed  CAS  Google Scholar 

  31. Betarbet R, Sherer TB, MacKenzie G et al (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306

    Article  PubMed  CAS  Google Scholar 

  32. Sherer TB, Betarbet R, Stout AK et al (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci 22:7006–7015

    PubMed  CAS  Google Scholar 

  33. Brown TP, Rumsby PC, Capleton AC et al (2006) Pesticides and Parkinson’s disease—is there a link? Environ. Health Perspect 114:156–164

    Article  Google Scholar 

  34. Dexter DT, Holley AE, Flitter WD (1994) Increase levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 9:92–97

    Article  PubMed  CAS  Google Scholar 

  35. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson′s disease. Ann Neurol 44:72–84

    Google Scholar 

  36. Beal MF (2002) Oxidatively modified proteins in aging and disease. Free Radic Biol Med 32:797–803

    Article  PubMed  CAS  Google Scholar 

  37. Connolly GP (2001) Cell imaging and morphology. Application to studies of inherited purine metabolic disorders. Pharmacol Ther 90:267–281

    Article  PubMed  CAS  Google Scholar 

  38. Mennini T, Bernasconi P, Bombardelli E et al (1993) In vitro study on the interaction of extracts and pure compounds from Valeriana officinalis roots with GABA, benzodiazepine and barbiturate receptors in rat brain. Fitoterapia 64:291–300

    CAS  Google Scholar 

  39. Han D, Zhang QG, Yong-Liu et al (2008) Co-activation of GABA receptors inhibits the JNK3 apoptotic pathway via the disassembly of the GluR6-PSD95-MLK3 signaling module in cerebral ischemic-reperfusion. FEBS Lett 582(9):1298–1306

    Article  PubMed  CAS  Google Scholar 

  40. Newhouse K, Shih-Ling H, Chang SH, Cai B, Wang Y, Xia Z (2004) Rotenone-Induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells. Toxicol Sci 79:137–146

    Article  PubMed  CAS  Google Scholar 

  41. Chen S, Zhang X, Yang D, Du Y, Li L, Li X, Ming M, Le W (2008) D2/D3 receptor agonist ropinirole protects dopaminergic cell line against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways. FEBS Lett 582(5):603–610

    Article  PubMed  CAS  Google Scholar 

  42. Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B (2008) Modulation of GABAA receptors by valerian extracts is related to the content of valerenic acid. Planta Med 74(1):19–24

    Article  PubMed  CAS  Google Scholar 

  43. Wasowski C, Marder M, Viola H et al (2002) Isolation and identification of 6-methylapigenin, a competitive ligand for the brain GABA(A) receptors, from Valeriana wallichii. Planta Med 68:934–936

    Article  PubMed  CAS  Google Scholar 

  44. Youdim KA, Spencer JP, Schroeter H et al (2002) Dietary flavonoids as potential neuroprotectants. Biol Chem 383:503–519

    Article  PubMed  CAS  Google Scholar 

  45. Ahlemeyer B, Krieglstein J (2003) Neuroprotective effects of Ginkgo biloba extract. Cell Mol Life Sci 60:1779–1792

    Article  PubMed  CAS  Google Scholar 

  46. Dajas F, Rivera F, Blasina F et al (2003) Cell culture protection and in vivo neuroprotective capacity of flavonoids. Neurotoxicity Res 5:425–432

    Google Scholar 

  47. Silva BA, Dias ACP, Ferreres F et al (2004) Neuroprotective effect of H. perforatum extracts on beta-amyloid-iduced neurotoxicity. Neurotoxicity Res 6(2):119–130

    Google Scholar 

  48. Areias FM, Rego AC, Oliveira CR et al (2001) Antioxidant effect of flavonoids after ascorbate/Fé(2 +)-induced oxidative stress in cultured retinal cells. Biochem Pharmacol 62:111–118

    Article  PubMed  CAS  Google Scholar 

  49. Prior RL (2003) Fruits and vegetables in the prevention of cellular oxidative damage. Am J Clin Nutr 78(Suppl. 3):570S–578S

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Fundação de Amparo a Pesquisa do Estado da Bahia (PRODOC/FAPESB 016/2004) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (FAPESB/CNPq 159/203), Brazil. We wish to thank Prof. Rex Davis for language supervision.

Author information

Authors and Affiliations

  1. Laboratório de Neuroquímica e Biologia Celular, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil

    Diêgo Madureira de Oliveria, George Barreto, Deyse Valverde G. De Andrade, Ramon Dos Santos El Bachá & Lisandro Diego Giraldez

  2. Desembargador Ezequiel Pondé 130, CEP 40155050, Salvador, Bahia, Brazil

    Lisandro Diego Giraldez

  3. Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos Aires (UBA), Buenos Aires, Argentina

    Ezequiel Saraceno, Laura Aon-Bertolino & Francisco Capani

Authors
  1. Diêgo Madureira de Oliveria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George Barreto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deyse Valverde G. De Andrade
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ezequiel Saraceno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Aon-Bertolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francisco Capani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ramon Dos Santos El Bachá
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Lisandro Diego Giraldez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisandro Diego Giraldez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Oliveria, D.M., Barreto, G., De Andrade, D.V.G. et al. Cytoprotective Effect of Valeriana officinalis Extract on an In Vitro Experimental Model of Parkinson Disease. Neurochem Res 34, 215–220 (2009). https://doi.org/10.1007/s11064-008-9749-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-008-9749-y

Keywords

Search

Navigation